0001105806-17-000005.txt : 20170214 0001105806-17-000005.hdr.sgml : 20170214 20170213190525 ACCESSION NUMBER: 0001105806-17-000005 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20170214 DATE AS OF CHANGE: 20170213 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Cidara Therapeutics, Inc. CENTRAL INDEX KEY: 0001610618 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 461537286 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-88806 FILM NUMBER: 17601588 BUSINESS ADDRESS: STREET 1: 6310 NANCY RIDGE DRIVE STREET 2: SUITE 101 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-752-6170 MAIL ADDRESS: STREET 1: 6310 NANCY RIDGE DRIVE STREET 2: SUITE 101 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: K2 THERAPEUTICS, INC. DATE OF NAME CHANGE: 20140611 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: LYTTON LAURENCE W CENTRAL INDEX KEY: 0001105806 FILING VALUES: FORM TYPE: SC 13G/A MAIL ADDRESS: STREET 1: 467 CPW CITY: NY STATE: NY ZIP: 10025 SC 13G/A 1 cdtx.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment 1) (Name of Issuer) Cidara Therapeutics, Inc (Title of Class of Securities) Common Stock (CUSIP Number) 71757107 (Date of Event Which Requires Filing of this Statement) December 31, 2016 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ]Rule 13d-1(b) [ X ]Rule 13d-1(c) [ ]Rule 13d-1(d) CUSIP No. 71757107 1.Names of Reporting Persons. Laurence W.Lytton 2. Check the Appropriate Box if a Member of a Group (See Instructions) a).......................................................................... (b).......................................................................... 3.SEC Use Only 4.Citizenship or Place of Organization USA 5.Sole Voting Power 553,475 6.Shared Voting Power 41,120 7.Sole Dispositive Power 553,475 8.Shared Dispositive Power 41,120 9.Aggregate Amount Beneficially Owned by Each Reporting Person 594,595 10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)................................. 11.Percent of Class Represented by Amount in Row (9) 3.6% 12.Type of Reporting Person (See Instructions) IN Item 1. (a)Name of Issuer Cidara Therapeutics, Inc (b)Address of Issuer's Principal Executive Offices 6310 Nancy Ridge Drive San Diego, CA 92121 Item 2. (a)Name of Person Filing Laurence W. Lytton (b)Address of Principal Business Office or, if none, Residence 467 CPW New York, NY 10025 (c)Citizenship USA (d)Title of Class of Securities Common (e)CUSIP Number 71757107 Item 3. not applicable Item 4.Ownership. (a)Amount beneficially owned: 594,595 shares consisting of 508,852 shares held by the reporting person, 32,525 held in the AWL Family LLC, 3,955 held in the IKL Trust, 9,893 held in the KLL Family Trust, 17,772 held in the WWL Family Trust, 9,528 held in the Lytton-Kambara Foundation and 12,070 shares held in other related accounts. (b)Percent of class: 3.6% (c)Number of shares as to which the person has: (i)Sole power to vote or to direct the vote 553,475. (ii)Shared power to vote or to direct the vote 41,120 (iii)Sole power to dispose or to direct the disposition of 553,475. (iv)Shared power to dispose or to direct the disposition of 41,120 Item 5.Ownership of Five Percent or Less of a Class: If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following (X). Item 6.Ownership of More than Five Percent on Behalf of Another Person. Not applicable Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company Not applicable Item 8.Identification and Classification of Members of the Group Not applicable Item 9.Notice of Dissolution of Group Not applicable Item 10.Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. __02/13/17____________________________ Date ____s/ Laurence W. Lytton____________________________ Signature _____Laurence W. Lytton___________________________ Name/Title